Ventyx Biosciences, Inc. — Investor Relations & Filings
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company that develops innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases. The company utilizes its expertise in medicinal chemistry, structural biology, and immunology to discover and advance differentiated small molecule therapeutics for conditions with high unmet medical needs. Its clinical pipeline features a portfolio of NLRP3 inhibitors, including VTX2735, a peripherally restricted candidate in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant candidate in Phase 2 for neurodegenerative and cardiometabolic diseases. Additionally, its inflammatory bowel disease portfolio includes tamuzimod, an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase 2 clinical trials.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 4 - VENTYX BIOSCIENCES, INC. (0001851194) (Filer) | 2026-03-04 | English | |
| 4 - VENTYX BIOSCIENCES, INC. (0001851194) (Filer) | 2026-03-04 | English | |
| 4 - VENTYX BIOSCIENCES, INC. (0001851194) (Filer) | 2026-03-04 | English | |
| 4 - VENTYX BIOSCIENCES, INC. (0001851194) (Filer) | 2026-03-04 | English | |
| 4 - VENTYX BIOSCIENCES, INC. (0001851194) (Filer) | 2026-03-04 | English | |
| 4 - VENTYX BIOSCIENCES, INC. (0001851194) (Filer) | 2026-03-04 | English |
Browse filings by year
6 yearsMarket data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
CATALYST PHARMACEUTICALS, INC.
Biopharmaceutical company commercializing drugs for rare ne…
|
CPRX | US | Manufacturing |
|
cbdMD, Inc.
Producer and distributor of health and wellness CBD product…
|
YCBD | US | Manufacturing |
|
CCSB
Specialized manufacturer of APIs for oncology, antifungal, …
|
1762 | TW | Manufacturing |
|
CDT Equity Inc.
A clinical-stage biopharmaceutical firm advancing assets fo…
|
CDT | US | Manufacturing |
|
Ceapro Inc.
Develops and commercializes natural active ingredients deri…
|
CZO | CA | Manufacturing |
|
CELADON PHARMACEUTICALS PLC
Researches, cultivates, and manufactures cannabinoid-based …
|
CEL | GB | Manufacturing |
|
Celemics, Inc.
Develops NGS target enrichment solutions for research and c…
|
331920 | KR | Manufacturing |
|
Cellbion Co., Ltd
Develops radiopharmaceuticals and radioligand therapies for…
|
308430 | KR | Manufacturing |
|
CELL BIOTECH CO ., LTD
Develops and manufactures probiotic solutions using patente…
|
049960 | KR | Manufacturing |
|
Celldex Therapeutics, Inc.
Develops antibody-based immunotherapies for severe inflamma…
|
CLDX | US | Manufacturing |
Ventyx Biosciences, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33798/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33798 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33798 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33798 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33798}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Ventyx Biosciences, Inc. (id: 33798)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.